Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3 | Zendy

William Lumry | Zendy; Henriette Farkas | Zendy; Dumitru Moldovan | Zendy; Elias Toubi | Zendy; Jovanna Baptista | Zendy; Timothy Craig | Zendy; Marc A. Riedl | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

Author(s) -

William Lumry,

Henriette Farkas,

Dumitru Moldovan,

Elias Toubi,

Jovanna Baptista,

Timothy Craig,

Marc A. Riedl

Publication year - 2015

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000441060

Subject(s) - icatibant , hereditary angioedema , medicine , angioedema , open label , clinical endpoint , gastroenterology , randomized controlled trial , dermatology , antagonist , receptor

In randomized, controlled, double-blind, multicenter phase 3 studies, one icatibant injection was efficacious and generally well tolerated in patients with a single hereditary angioedema (HAE) attack. Here, the efficacy and safety of icatibant for multiple HAE attacks was evaluated across the controlled and open-label extension phases of the For Angioedema Subcutaneous Treatment (FAST)-3 study (NCT00912093).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research